Compare OBK & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBK | ANAB |
|---|---|---|
| Founded | 1912 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2018 | 2015 |
| Metric | OBK | ANAB |
|---|---|---|
| Price | $45.31 | $62.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $46.67 | ★ $71.67 |
| AVG Volume (30 Days) | 158.4K | ★ 616.1K |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 0.89 | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | $26.43 | N/A |
| Revenue Next Year | $5.79 | $52.14 |
| P/E Ratio | $51.83 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $32.13 | $17.11 |
| 52 Week High | $48.12 | $73.30 |
| Indicator | OBK | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 47.76 | 48.23 |
| Support Level | $42.75 | $53.46 |
| Resistance Level | $46.02 | $70.26 |
| Average True Range (ATR) | 1.13 | 4.70 |
| MACD | -0.31 | -0.49 |
| Stochastic Oscillator | 8.17 | 35.15 |
Origin Bancorp Inc is a financial holding company that provides personalized, relationship banking to businesses, municipalities, and personal clients in the communities it serves. The company offers a broad range of financial services and operates more than 56 locations in Dallas/Fort Worth, East Texas, Houston, North Louisiana, Mississippi, South Alabama, and the Florida Panhandle. It also provides insurance agency products and services through its wholly owned insurance agency subsidiary. The company operates in one business segment, community banking, and is mainly engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).